This company listing is no longer active
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Clover Biopharmaceuticals 過去の業績
過去 基準チェック /06
Clover Biopharmaceuticals's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 12.7% annually.
主要情報
-16.2%
収益成長率
-13.6%
EPS成長率
| Biotechs 業界の成長 | 11.0% |
| 収益成長率 | n/a |
| 株主資本利益率 | -2,329.7% |
| ネット・マージン | -258,830.4% |
| 前回の決算情報 | 30 Jun 2023 |
最近の業績更新
Recent updates
収支内訳
Clover Biopharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -665 | 317 | 996 |
| 31 Mar 23 | 0 | -1,559 | 364 | 1,230 |
| 31 Dec 22 | 0 | -2,452 | 410 | 1,465 |
| 30 Sep 22 | 0 | -4,145 | 428 | 1,757 |
| 30 Jun 22 | 0 | -5,838 | 446 | 2,048 |
| 31 Mar 22 | 0 | -5,927 | 396 | 1,937 |
| 31 Dec 21 | 0 | -6,016 | 346 | 1,826 |
| 31 Dec 20 | 0 | -913 | 76 | 228 |
質の高い収益: 2197 is currently unprofitable.
利益率の向上: 2197 is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 2197 is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.
成長の加速: Unable to compare 2197's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: 2197 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
株主資本利益率
高いROE: 2197 has a negative Return on Equity (-2329.68%), as it is currently unprofitable.